3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
8
Phase 1/2
3
Phase NA
1
Phase 4
1
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
3
Fallopian Tube Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Hematologic Neoplasms
1
HER2-ve Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
olaparib
×
Clear all
NCT04421963
2026-04-16
ROSY-O
AstraZeneca
Phase 3
Active not recruiting
185 enrolled